Evolent Health, Inc (NYSE:EVH) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Evolent Health, Inc (NYSE:EVH) have received an average rating of “Moderate Buy” from the sixteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $10.7143.

Several equities research analysts have commented on EVH shares. Citizens Jmp cut their target price on Evolent Health from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Tuesday. Stephens raised shares of Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 price objective on the stock in a research report on Thursday, November 13th. BTIG Research reduced their target price on shares of Evolent Health from $20.00 to $16.00 and set a “buy” rating for the company in a report on Friday, November 7th. Oppenheimer lowered their price target on shares of Evolent Health from $18.00 to $12.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 12th. Finally, Citigroup cut their price target on shares of Evolent Health from $9.50 to $6.00 and set a “buy” rating on the stock in a research report on Friday.

Evolent Health Price Performance

Shares of NYSE EVH opened at $4.16 on Monday. The company has a fifty day moving average price of $4.29 and a 200 day moving average price of $7.57. The firm has a market cap of $463.70 million, a PE ratio of -2.63 and a beta of 0.26. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 1.25. Evolent Health has a 1-year low of $3.49 and a 1-year high of $12.98.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Tuesday, June 4th. The technology company reported $0.21 earnings per share (EPS) for the quarter. The firm had revenue of $427.70 million for the quarter. Evolent Health had a positive return on equity of 1.79% and a negative net margin of 6.24%. Research analysts predict that Evolent Health will post 0.08 earnings per share for the current fiscal year.

Insider Transactions at Evolent Health

In related news, Director Brendan B. Springstubb purchased 10,000 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was purchased at an average cost of $3.82 per share, for a total transaction of $38,200.00. Following the completion of the purchase, the director directly owned 58,821 shares in the company, valued at $224,696.22. This trade represents a 20.48% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Evolent Health

Hedge funds and other institutional investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its holdings in Evolent Health by 88.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock worth $29,000 after buying an additional 1,194 shares during the last quarter. CIBC Private Wealth Group LLC grew its position in shares of Evolent Health by 4,000.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock valued at $35,000 after acquiring an additional 4,000 shares during the period. Parallel Advisors LLC increased its stake in shares of Evolent Health by 82.6% during the 2nd quarter. Parallel Advisors LLC now owns 3,487 shares of the technology company’s stock worth $39,000 after purchasing an additional 1,577 shares during the last quarter. Strs Ohio bought a new stake in shares of Evolent Health in the 1st quarter valued at about $47,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in Evolent Health in the 3rd quarter valued at about $51,000.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.